Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03088878 | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 95 | Oncternal Therapeutics, IncINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT04517435 |
| ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma |
| terminated |
| Phase 1 / Phase 2 |
| 13 |
| Deepa JagadeeshOTHER |
| 1 |
| Feb 7, 2025 |
| clinicaltrials |
| NCT06464861 | Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma(CD19-CARNK/T) | recruiting | Phase 1 | 52 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03636503 | Rituximab + Immunotherapy in Follicular Lymphoma | terminated | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT04599634 | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 4, 2025 | clinicaltrials |
| NCT02743546 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma | withdrawn | Phase 1 | 0 | Janssen Research & Development, LLCINDUSTRY | 0 | Feb 3, 2025 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02112526 | Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma | completed | Phase 1 | 21 | Acerta Pharma BVINDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT03129828 | Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2(ImbruVeRCHOP) | completed | Phase 1 / Phase 2 | 38 | Prof. Dr. Clemens SchmittOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03410901 | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | completed | Phase 1 | 14 | Ronald LevyOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05233033 | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL | completed | Phase 1 | 7 | Kymera Therapeutics, Inc.INDUSTRY | 2 | Dec 10, 2024 | clinicaltrials |
| NCT03153202 | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | active not recruiting | Phase 1 / Phase 2 | 23 | Joshua BrodyOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02268851 | A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL | completed | Phase 1 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT03955783 | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | completed | Phase 1 | 78 | Sanjay MohanOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | terminated | Phase 1 / Phase 2 | 46 | GenmabINDUSTRY | 5 | Oct 24, 2024 | clinicaltrials |
| NCT03340766 | Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)(HARBOUR) | completed | Phase 1 | 31 | AmgenINDUSTRY | 6 | Oct 17, 2024 | clinicaltrials |
| NCT02927964 | TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | completed | Phase 1 / Phase 2 | 21 | Robert LowskyOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04134936 | Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | completed | Phase 1 | 66 | MorphoSys AGINDUSTRY | 9 | Oct 16, 2024 | clinicaltrials |
| NCT06635330 | Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL | recruiting | Phase 1 / Phase 2 | 5 | Kara Yakhteh Tajhiz Azma CompanyNETWORK | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03136497 | A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 1 | 10 | Hackensack Meridian HealthOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06593145 | CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms(CARLA) | recruiting | Phase 1 | 6 | FamiCordTxINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05333302 | Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma | unknown | Phase 1 | 10 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04274738 | A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | completed | Phase 1 | 16 | X4 PharmaceuticalsINDUSTRY | 2 | Aug 27, 2024 | clinicaltrials |
| NCT06047197 | Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 25 | Beijing Yongtai Ruike Biotechnology Company LtdINDUSTRY | 1 | Aug 27, 2024 | clinicaltrials |
| NCT04049513 | ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)(ENABLE-1) | active not recruiting | Phase 1 | 30 | Malaghan Institute of Medical ResearchOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04450069 | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies | completed | Phase 1 | 18 | Calibr, a division of Scripps ResearchOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT00487305 | Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04682808 | A Study of FCN-338 in Patients With Chronic CLL/SLL | unknown | Phase 1 | 99 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04914741 | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)(COALITION) | unknown | Phase 1 / Phase 2 | 80 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06547944 | Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)(ZGR in TN CLL) | active not recruiting | Phase 1 | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05749549 | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | unknown | Phase 1 / Phase 2 | 191 | Shanghai Blueray Biopharma Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | terminated | Phase 1 | 21 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03245021 | Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A(1stFLOR) | active not recruiting | Phase 1 | 39 | Dr. Eliza HawkesOTHER_GOV | 1 | Jul 30, 2024 | clinicaltrials |
| NCT03676504 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | recruiting | Phase 1 / Phase 2 | 68 | University Hospital HeidelbergOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT03980171 | Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma(LEVERAGE) | active not recruiting | Phase 1 / Phase 2 | 50 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04082936 | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 97 | IGM Biosciences, Inc.INDUSTRY | 7 | Jul 24, 2024 | clinicaltrials |
| NCT06517004 | An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05360238 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | terminated | Phase 1 / Phase 2 | 20 | Mustang BioINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT05272813 | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | terminated | Phase 1 / Phase 2 | 13 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05720052 | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | terminated | Phase 1 / Phase 2 | 8 | MingSight Pharmaceuticals, IncINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05936229 | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT04555811 | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL | completed | Phase 1 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT04933617 | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas | terminated | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02295722 | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma(GEMHDM2014) | terminated | Phase 1 / Phase 2 | 100 | AHS Cancer Control AlbertaOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03422393 | Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib | active not recruiting | Phase 1 | 24 | Michael ChoiOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT02628405 | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT02631044 | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | completed | Phase 1 | 387 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 12, 2025source: clinicaltrials